Latest News
-
Thursday - February 25, 2021
Financial News Conference
Full Year 2020 Results » more
-
Thursday - February 25, 2021
Fiscal 2020:
Bayer delivers robust performance despite pandemic – foundation laid for future growth
Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent) / EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management / Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth / Core earnings per share at 6.39 euros (plus 0.2 percent) / Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments / Net financial debt improves by 11.8 percent to 30.041 billion euros / Proposed dividend of 2.00 euros per share (2019: 2.80 euros) / Portfolio and innovation capabilities strengthened / Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies » more
-
Wednesday - February 24, 2021
Bayer to Divest Environmental Science Professional Business and Further Strengthen Leadership Team of Crop Science Division » more
-
Monday - February 22, 2021
Bayer strives for gender parity in all management levels by 2030, advances overall inclusion and diversity approach » more
-
Wednesday - February 17, 2021
Prestigious Award from the Bayer Foundation:
Otto Bayer Award goes to Prof. Ruth Ley PhD
Director of the Department of Microbiome Research at the Max Planck Institute for Developmental Biology in Tübingen is honored for outstanding achievements in her field / Four young scientists receive the Bayer Early Excellence in Science Award / Werner Baumann: “The Bio Revolution has the potential to transform our economies and contribute to overcoming global challenges.” » more
-
Monday - February 15, 2021
Bayer Future of Farming Dialogue:
Bayer Fueling Growth Opportunities for Sustainable Agriculture Through Collaborative Innovation Model
Unique Open Innovation model, alongside Leaps by Bayer impact investments, drive future agricultural advancements in gene editing, plant health and improved food quality / Leveraging the latest agricultural technologies in new ways to reduce environmental impact and solve big challenges in food and agriculture » more
-
Monday - February 15, 2021
Bayer Wuppertal:
North Rhine-Westphalia’s State Premier Armin Laschet visits future Bayer AG vaccine production site » more
-
Tuesday - February 9, 2021
Not intended for U.S. and UK Media
Bayer submits finerenone for marketing authorization in China for the treatment of chronic kidney disease in type 2 diabetes » more
-
Monday - February 8, 2021
Not intended for U.S. and UK Media
New data presented at 2021 ASCO GU Cancers Symposium add to robustness of the overall survival benefit and favorable safety profile for Nubeqa™
New analyses from the Phase III ARAMIS trial further strengthen the overall survival benefit and favorable safety profile of darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Additional data from darolutamide and radium-223 dichloride (Xofigo™) trials demonstrate Bayer’s continued commitment to ongoing prostate cancer research to bring meaningful benefit to the lives of men across different stages of the disease / Expert-led and patient perspectives as well as additional prostate cancer educational resources for media can be found on Bayer’s ASCO GU Virtual Media Hub » more
-
Monday - February 8, 2021
Not intended for U.S. and UK Media
Bayer and Orion expand development program for darolutamide in prostate cancer
Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy / Start of patient enrollment expected by the end of Q1 2021 / Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients with prostate cancer » more
-
Wednesday - February 3, 2021
Bayer announces agreement with plaintiffs’ counsel on class plan
Motion for preliminary approval is being filed for program designed to manage and resolve future Roundup™ litigation » more
-
Wednesday - February 3, 2021
Not intended for U.S. and UK Media
Bayer receives approval for Nubeqa™ in China for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) » more
-
Wednesday - February 3, 2021
Horsch, The Climate Corporation announce platform agreement
Farmers will have increased opportunity to access and apply digital tools and Bayer data science capabilities » more
-
Tuesday - February 2, 2021
Bayer launches The Nutrient Gap Initiative to Expand Access to Vitamins and Minerals for 50 Million People Annually Worldwide by 2030
Primary Focus will be on Most Vulnerable – Pregnant Women and Children in Underserved Communities » more
-
Monday - February 1, 2021
Bayer to manufacture mRNA vaccine in Germany » more
-
Wednesday - January 27, 2021
New Leaps by Bayer investment:
Ukko secures USD 40 million in Series B funding led by Leaps by Bayer to overcome food allergies and sensitivities
Top industry leaders and venture firms unite behind Ukko’s efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten » more
-
Friday - January 22, 2021
Not intended for U.S. and UK Media
Japan approves rivaroxaban (XareltoTM) to treat children with venous thromboembolism (VTE) and to prevent recurrence
Pediatric patients currently have limited therapeutic options available / Granules for oral suspension of rivaroxaban that does not require regular coagulation monitoring has been developed and approved to facilitate pediatric administration / Pediatric use is based on the largest pediatric thromboembolism program completed to date, EINSTEIN-Jr. » more
-
Wednesday - January 20, 2021
Not intended for U.S. and UK Media
U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure
Vericiguat (Verquvo®) is the first soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of symptomatic chronic heart failure / Vericiguat works on a pathway not currently targeted by existing heart failure treatments » more
-
Tuesday - January 19, 2021
Scientist Discovers New Bee Species on Bayer Partner Farm in Brazil
Its official name is Ceratina (Ceratinula) fioreseana, which is now one of 38 known bee species within the Ceratinula subgenus located throughout the Americas / This new species does not live in colonies or produce honey, but it belongs to a group of important pollinators » more
-
Wednesday - January 13, 2021
Not intended for U.S. and UK Media - Virtual Bayer Pharma Media Day:
Bayer transforms pharma business through breakthrough innovation in healthcare
Emerging leadership in field of cell and gene therapies / Accelerating breakthrough innovation for patients / Innovation in field of digital health solutions to become key pillar of Bayer’s pharmaceutical business empowering patients with Integrated Care offerings / Promising development portfolio with more than 50 projects in clinical development phases » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Wednesday, March 10, 2021
Virtual Capital Markets Day 2021
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV